Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Padeliporfin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 08 Jan 2018 Status changed from recruiting to discontinued due to concerns about post VTP MRI results being conclusive
- 10 Aug 2015 Accrual to date is 62 % according to United Kingdom Clinical Research Network.
- 08 Aug 2015 Accrual to date is 50% according to United Kingdom Clinical Research Network.